Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BZ019
- Development stage
- Phase 2
- Lead developer
- Shanghai Cell Therapy Group
- Modality
- Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BZ019 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19, a tumor-associated antigen expressed on the surface of B cells. The therapy involves genetically modifying a patient's own T lymphocytes using a non-viral vector to express a CAR that recognizes and binds to CD19, leading to targeted immunologic cytotoxicity against malignant B cells. It is being developed primarily for the treatment of relapsed or refractory large B-cell lymphoma and other high-grade or diffuse large B-cell lymphomas. The product is under development by Shanghai Cell Therapy Group and related organizations, with clinical trials reaching up to Phase 2 before being suspended[1][2][3][4][5].
- Other names
- non-viral CD19 CAR-Tnon-viral CD19-targeted CAR-T cells
02
Targets
Beyond the preview
Go deeper on BZ019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BZ019.